Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

NCT05327686 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05327686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05327686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Lead sponsor
NRG Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
February 1, 2023
Completion date
June 15, 2033
Enrollment
240 (estimated)
Sites
328

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8, unresectable renal cell carcinoma